| 3rd Jun 2019 3:00 pm |
RNS |
Block listing Interim Review |
| 3rd Jun 2019 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Jun 2019 7:00 am |
RNS |
Lynparza nearly doubled time patients lived with |
| 10th May 2019 7:00 am |
RNS |
Pooled analyses of the roxadustat global Phase III |
| 8th May 2019 2:00 pm |
RNS |
Director/PDMR Shareholding |
| 8th May 2019 11:00 am |
RNS |
Director Declaration |
| 8th May 2019 7:00 am |
RNS |
Trastuzumab deruxtecan demonstrated clinically |
| 7th May 2019 7:00 am |
RNS |
Calquence PhIII ASCEND trial met primary endpoint |
| 3rd May 2019 7:00 am |
RNS |
Qternmet XR approved in the US for type-2 diabetes |
| 1st May 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st May 2019 12:00 pm |
RNS |
Director/PDMR Shareholding |
| 29th Apr 2019 7:00 am |
RNS |
Lynparza receives positive EU CHMP opinion for 1st |
| 26th Apr 2019 5:45 pm |
RNS |
Result of AGM |
| 26th Apr 2019 7:00 am |
RNS |
AZN: Q1 2019 Results |
| 10th Apr 2019 7:00 am |
RNS |
Lynparza approved in EU for the treatment of germl |
| 9th Apr 2019 4:10 pm |
EQS |
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales |
| 4th Apr 2019 1:30 pm |
RNS |
Holding(s) in Company |
| 3rd Apr 2019 10:00 am |
RNS |
Director/PDMR Shareholding |
| 2nd Apr 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Apr 2019 6:00 pm |
RNS |
Astrazeneca |
| 1st Apr 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Apr 2019 7:00 am |
RNS |
Selumetinib gets Breakthrough Therapy Designation |
| 29th Mar 2019 5:15 pm |
RNS |
Results of Placing |
| 29th Mar 2019 7:00 am |
RNS |
Proposed placing of new ordinary shares |
| 29th Mar 2019 7:00 am |
RNS |
AZ and Daiichi Sankyo enter collaboration in novel |
| 27th Mar 2019 7:00 am |
RNS |
Forxiga approved in Japan for type-1 diabetes |
| 25th Mar 2019 7:00 am |
RNS |
Forxiga approved in Europe for type-1 diabetes |
| 18th Mar 2019 7:00 am |
RNS |
US FDA grants saracatinib ODD for IPF |
| 14th Mar 2019 12:00 pm |
RNS |
Notice of AGM |
| 12th Mar 2019 12:00 pm |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2019 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 5th Mar 2019 11:00 am |
RNS |
Annual Financial Report |
| 4th Mar 2019 4:04 pm |
RNS |
Holding(s) in Company |
| 1st Mar 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Mar 2019 1:45 pm |
RNS |
Lynparza receives positive EU CHMP opinion |
| 26th Feb 2019 7:00 am |
RNS |
Lynparza significantly delayed disease progression |
| 25th Feb 2019 7:00 am |
RNS |
Brilinta's PhIII THEMIS trial met primary endpoint |
| 14th Feb 2019 7:00 am |
RNS |
AstraZeneca Full-Year and Q4 2018 Results |
| 6th Feb 2019 7:00 am |
RNS |
US FDA grants Fasenra Orphan Drug Designation |
| 5th Feb 2019 7:05 am |
RNS |
US FDA grants Breakthrough Therapy Designation |
